Antares Pharma, Inc.

Actinium Pharmaceuticals, Limited

Kaushik J Dave

Paul K Wotton

Hermanus L Jooste

Peter L Sadowski

Jonathan Jaffe

Shubh D Sharma

John William Hayes

Dominic P Capone

Yulian Zhang

Jon Jaffe

The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.

Administration of testosterone compositions

Needle assisted jet injection administration of testosterone compositions

Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radio-therapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.

Stabilized radiolabeled anti-CD45 immunoglobulin compositions

Stabilized radio-labeled anti-CD45 immunoglobulin compositions

Needle assisted injection administration of testosterone compositions

A patient specific therapeutic composition provided in a single dose container, the total volume of which may be administered to a patient in a single treatment session. The composition includes a monoclonal antibody having a labeled fraction and an unlabeled fraction, and a pharmaceutically acceptable carrier. The label may be any of a radioisotope or a drug such as a chemotherapeutic or cytotoxic agent. The amount of the monoclonal antibody and any conjugated label molecule may depend on at least one patient specific parameter selected from a patient weight, a patient age, a patient height, a patient gender, a patient medical condition, and a patient medical history. Methods of administration, production, and articles of manufacture comprising the patient specific therapeutic composition are also disclosed.

Infusion administration of conjugated monoclonal antibodies

The present disclosure relates, in part, to a kit including at least two prefilled syringes. The first prefilled syringe includes a dose of a hazardous agent in a first volume of a pharmaceutical composition comprising a pharmaceutically acceptable solvent.

Prefilled syringes and kits thereof

Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radiotherapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.

Growing community of inventors

Edison, NJ, United States of America

Kaushik J Dave